# 1. Financial Performance ## A. Key Figures * **GWP (H1 FY'26):** **₹3,983 Cr** (like-to-like, +23%) * **PAT (IFRS):** **₹132 Cr** (+120% YoY) * **Combined Ratio (IFRS):** **103.1%** (–105 bps) driven by **–2.3% expense ratio** · **+1.2% loss ratio** * **Investment AUM:** **₹8,482 Cr** (+4–5% since Mar'25) * Solvency Ratio: 2.85x (as of 30-Sep-25) * Annualized Investment Yield: 7.3% * **Debt Portfolio Duration:** **61 months** ## B. Revenue Growth * **Growth Clarity:** Management emphasized use of **IFRS financials excluding 1/N impact** for accurate like-to-like comparisons due to ongoing revenue recognition changes. * **Revenue Timing Effect:** Current-year reported premiums are **elevated** due to inclusion of deferred revenue from prior periods under the new 1/N policy. ## C. Profitability Trends * **Strong Bottom-Line Expansion:** PAT more than doubled on **robust underwriting performance**, with combined ratio improvement driven by **significant expense discipline** despite higher loss ratio. ## D. Balance Sheet Strength * **Capital Resilience:** Solvency ratio of **85x** and stable AUM reflect a **conservative, well-capitalized balance sheet**. * **Advance Premium Disclosure:** Figures not yet public; will be disclosed separately via **IRDAI filings**. ## E. Cash Flow Trends * **Flat AUM Growth:** Investment AUM saw only **marginal expansion** between March and September 2025, with no strategic explanation provided. --- # 2. Product & Segment Performance ## A. Key Figures * **Retail Health GWP Growth:** **28%** H1 YoY (volume-driven) · **6–7%** value growth contribution * **Group Health Premium Growth:** **13%** H1 YoY · **6%** QoQ YoY (slowing trend) * **Porting Policies:** Stable at **20–25%** of total premium/GWP * **SME & Large Corporate Growth:** **40–50%** growth in two key segments last year, now sustaining **double-digit growth** ## B. Retail Health Growth * **Transformational Tech Rollout:** Launch of modern **microservices-based core system** and ReAssure 0 platform set to accelerate product innovation and enhance customer service. * **Strong Volume-Led Expansion:** Retail health GWP growth reflects **robust demand and distribution reach**, with a small but meaningful contribution from value-based levers. * **Strategic Priority Confirmed:** Management reaffirmed retail health insurance as a **core growth pillar**, supported by digital capabilities recognized in Bupa’s global top 10. ## C. Group Health Trends * **Selective Underwriting Discipline:** Growth moderation driven by a shift from volume to **profitability-focused strategy**, evaluating opportunities on **combined ratio** and **COR metrics** rather than loss ratio alone. * **Corporate Indemnity Drag:** Slower growth concentrated in **corporate indemnity plans**, while **benefit-based plans** continue to grow in the **low teens**, reflecting disciplined client selection. * **Business Mix Clarity:** Employer-employee group business accounts for **one-third** of group premiums, with the majority (two-thirds) coming from **affinity arrangements**. ## D. Product Mix & Distribution * **Stable Core Mix:** Product and distribution mix remains consistent across segments, with **minor PPN expansion** (one new city) to improve care access and claims efficiency. * **Indemnity Dominance Persists:** In group health, **two-thirds of plans remain indemnity-based**, despite strategic emphasis on higher-margin benefit-based offerings. ## E. SME Segment Focus * **Disproportionate Strategic Emphasis:** Company maintains **targeted focus on SME segment** within group health, aligning with long-term profitability and underwriting control objectives. --- # 3. Distribution & Channel Mix ## A. Key Figures * Digital Active Users: 5.8 lakh monthly app users * **Digital Health Utilization:** **51,000+ health checkups** and **~6,700 doctor consultations** monthly via app * **Agent GWP per Policy:** ₹25,108 (Q1) · ₹25,215 (Q2) 1H average ## B. Digital Direct Growth * **Digital Momentum:** Digital direct business expanding at nearly **5x the company’s average growth rate**, underscoring strategic prioritization and scalability. * **User Engagement:** High engagement on digital platform with robust utilization of health services, signaling strong product-market fit and retention potential. * **Operational Control:** Limited outsourcing for IT manpower; active review for **in-sourcing opportunities** to enhance long-term efficiency and oversight. ## C. Agent Headcount & Productivity * **Distribution Expansion:** Added over **1,000 agents** this year, reinforcing ground-level reach and market penetration. * **AI Integration:** Launched dedicated **AI lab** to deploy Gen AI across sales enablement, customer experience, and cost optimization initiatives. * **Productivity Stability:** Agent-level gross written premium remained stable in 1H, with minor fluctuations attributed to **1/N metric distortion**, soon to be corrected. ## D. Distributor Commission Dynamics * **GST Benefit Passed Through:** Full GST benefit transferred to distributors, resulting in **higher overall income** despite lower per-policy margins due to volume and ticket size gains. * **Distributor Acceptance:** Distributors have responded positively to commission adjustments, recognizing long-term income growth from increased policy uptake and coverage depth. * **Commission Mix Shift:** Decline in gross commission ratio driven by business mix—growth in **employer-employee**, **new**, and **renewal business**—not channel reallocation. * **Resilience to Market Shifts:** Company’s performance remains unaffected by multiline peers’ **1/N commission strategy**, affirming competitive positioning. ## E. Channel-wise Premium Mix * **Broad-Based Growth:** October growth fueled by strong performance across **agency, digital direct, and digital partnerships**, indicating balanced channel momentum. --- # 4. Claims & Underwriting Metrics ## A. Key Figures * **Retail Loss Ratio (H1 FY'26):** **68%** IFRS (flat YoY) * Group Loss Ratio (H1 FY'26): 60.9% IFRS (+5 pp YoY) * Overall Group Health Loss Ratio: 65.9% (68.1% retail, 60.9% group) * **Claims Ratio Reserve Release:** **₹50 Cr**, now stable ## B. Loss Ratio Trends * **Retail Stability:** Retail loss ratio remains flat YoY, supported by **range-bound incidence rates** and **lower average claim sizes** due to benign medical inflation. * **Group Deterioration Offset by Expenses:** Group loss ratio increased on mix shift toward growing corporate accounts, but overall combined ratio improved due to **low expense ratios in large group deals**. * **Seasonal Pattern Intact:** Q2 saw a temporary uptick in claims ratio due to prior quarter’s backlog, but H1 trend remains stable and **YoY improvement evident** despite quarterly volatility. * **Forward Outlook Positive:** IFRS loss ratios expected to remain steady in H2, with a **favorable Q4 comparison** anticipated due to high-margin group business written last year. ## C. Claims Cost Control * **PPN Delivers Cost Savings:** Claims processed through PPN hospitals are **10–15% cheaper** than tertiary care for like-to-like treatments, reinforcing network efficiency. * **Moderate PPN Penetration:** Approximately **17% of claims** in PPN cities are routed through the network, indicating room for expansion and further cost optimization. ## D. PPN Network Usage * **PPN Scaling in 44 Cities:** Preferred Provider Network is operational in **44 cities**, with narrow network products still in early adoption at **single-digit % of new sales**. * **Industry-Wide Standardization:** SAHI players have adopted standardized clinical protocols for **7 conditions** and **10–12 diagnosis codes**, enhancing claims predictability and cost control. ## E. Renewal Rate Improvement * **Strong Renewal Momentum:** Renewal rates improved by **over 100 bps YoY**, with outsized gains in October, reflecting enhanced customer retention. * **Upsell Driving Policy Value:** Renewal upsell performance strengthened via higher sum insured and rider adoption, contributing to **higher ticket sizes**. --- # 5. Pricing & Demand Trends ## A. Key Figures * **Ticket Size Growth:** **+15%** retail new business ticket size in October vs. H1 ## B. GST Impact on Demand * **Major Affordability Boost:** 0% GST achieved after prolonged advocacy, significantly enhancing affordability and expected to catalyze health insurance adoption. * **Clean Q3 Ahead:** Pass-through to distributors effective October 1 eliminates GST drag; Q3 to reflect normalized performance with **no material GST impact**. * **Pricing Flexibility Under Review:** Potential for price hikes in 6–8 months remains uncertain; no changes planned for current quarter as company monitors volume response. ## C. Price Elasticity Effect * **Sector-Wide Demand Catalyst:** GST reduction confirms strong price elasticity in health insurance, with lower prices benefiting customers and distributors alike. * **Volume Over Margin Trade-off:** Short-term distributor income loss expected to be offset by **robust policy volume growth**, aligning with structural demand expansion. * **Claims-Based Pricing Allowed but Not Detailed:** Company acknowledges regulatory allowance for claim experience-based pricing, though implementation roadmap remains unspecified. ## D. Ticket Size & Customer Acquisition Trends * **Upsell Momentum:** 15% increase in retail ticket size driven by higher sum insured and improved adequacy, supported by enhanced analytics for targeted upselling. * **Behavioral Incentives Driving Engagement:** Discounts of **up to 30%** tied to health metrics (e.g., **10,000 daily steps**) encourage healthy behavior beyond claims history. * **Strong Acquisition Despite Seasonality:** Unusual demand surge in typically weak Diwali month, backed by rising Google queries and conversion rates, signaling effective customer pull. --- # 6. Risks & Regulatory Factors ## A. Key Figures * EOM Ratio: 36.3% stand-alone (–370 bps) · 35.8% group level (+50 bps vs. regulatory limit) * **GWP Growth:** **23%** in H1 FY'26 * **GST Rate:** Reduced from **18%** to **0%** on health insurance ## B. EOM Ratio Compliance * **Sharp EOM Improvement:** Stand-alone expense ratio fell sharply due to strong underwriting growth and operating leverage, despite low-single-digit expense inflation. * **Regulatory Pathway:** Group-level EOM remains above the regulatory threshold, but management is confident in achieving compliance via the **glide path submitted to IRDAI**. ## C. GST Input Tax Risk * **Full Commission Pass-Through:** Niva Bupa has fully transferred GST impact to distributors, eliminating ITC burden on its P&L. * **Cost Review Underway:** Management is actively reviewing **overhead costs with GST liability and no input credit**, targeting renegotiation, as **65–75% of commission costs** remain adjustable. * **Positive Behavioral Signal:** Early October data shows distributor acceptance of new structure, with rising volumes echoing **mutual fund industry’s 3x growth post-GST reform**. ## D. Underinsurance Challenge * **Structural Industry Issue:** Persistent underinsurance remains a key barrier, though **0% GST** is expected to improve affordability and penetration over time. ## E. Pricing Regulation * **Regulatory Flexibility:** IRDAI permits **pricing based on claim experience** and offers **discounts for favourable claims history**, providing levers for risk-based pricing. --- # 7. Guidance & Outlook ## A. Strategic Outlook & Commitments * **Sustained ROE Target:** Niva Bupa reaffirms long-term ROE ambition of **mid to high teens by FY '29**, unchanged despite near-term performance trends. * **Secular Growth Conviction:** Management views health insurance as a multi-decadal opportunity, backing this with **significant strategic investments** to capture market value. * **Investment Horizon:** Key growth initiatives, including referenced expansion plans, are structured over a **5-year duration**, underscoring long-term capital commitment. * **Profitable Expansion Mandate:** Company remains focused on scaling the health insurance business in a **profitable and sustainable** manner, emphasizing discipline in growth execution.